Navigation Links
Opexa Presents Tovaxin Research at Federation of Clinical,Immunology Societies Annual Meeting

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, made a poster presentation at the 2007 Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) in San Diego June 7-11 at the Sheraton San Diego Hotel & Marina. The poster, entitled "Identifying New Immunodominant Myelin Peptides in Relapsing Remitting Multiple Sclerosis Patients" was presented on Sunday, June 10.

The presentation covered laboratory and clinical data from the Company's proprietary T-cell vaccination technology for the treatment of multiple sclerosis. Key highlights of research detailed in the poster presentation include:

-- Data accumulated from over 173 assays (using a T-cell Epitope Analysis Assay (EAA)) have allowed Opexa to identify several myelin protein peptides from myelin basic protein (MBP), myelin proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG) as being immunodominant, including some peptides never before reported, and others as being non-reactive,

-- The EAA can be utilized to screen additional or combinations of peptides that have biological significance and;

-- These results have permitted Opexa to optimize the number of myelin peptides across the lengths of MBP, PLP and MOG in the screening assay for Tovaxin(TM) vaccine production to qualify subjects for Opexa's current 150-patient Phase IIb safety and efficacy clinical trial (TERMS).

"These findings mark an important development for Tovaxin, which is a patient-specific autologous T-cell vaccine, because it helps us qualify subjects for our current clinical trial and improves production of the vaccine. The EAA is an important assay for further refinement of the T-cell vaccination technology, which is truly personalized, to make the therapy as efficacious as possible for each patient," said
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:1/15/2014)... 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... support, China,s orthopedic instrument industry ... market size rising from 3.28 billion yuan in 2006 ...
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:4/24/2014)... of three survivors of critical illness, according to ... Respiratory Medicine , and the majority of patients ... It is one of the largest studies to ... critical care survivors, according to lead author James ... highlights a significant public health issue, with roughly ...
(Date:4/24/2014)... A Finnish team of researchers was the first in ... which is a tumour of the jaw. , Ameloblastoma ... recur after treatment. Ameloblastoma is most often found in ... by surgery, often resulting in tissue deficiencies in the ... suitable drug therapy could reduce the need for surgery ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
(Date:4/24/2014)... 2009 the influenza pH1N1 virus caused the first flu ... in May 2009 and killed more than 50 people ... Finns mainly during flu epidemics (winter/spring seasons). , ... serious complicated illnesses. World Health Organization has recommended Tamiflu ... The disadvantage of this drug is that it targets ...
(Date:4/23/2014)... (MGH) investigators may lead to greater availability and acceptability ... use of fecal material from healthy donors to ... ( C. difficile ) bacteria. In their ... Infectious Diseases , the researchers report that use of ... was as successful in curing recurrent C. difficile ...
Breaking Medicine News(10 mins):Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... Company-Sponsored "Technology Topics" Workshop Scheduled for 1 to ... Regency Century Plaza, Constellation Room A., WELLESLEY, ... in,the development of cost-effective, easy-to-use gene-expression analysis,systems, announced ... System for research use only at the Association ...
... Code Created for Minimally Invasive Procedure to Treat ... ... Endocare, Inc.,(Nasdaq: ENDO ), an innovative medical device company focused ... that the Centers for Medicare and Medicaid Services,(CMS) have accepted the ...
... Anke Linnartz (38) is,to assume responsibility for managing ... 1, 2008. In this position she will report ... supplier of high-quality packaging solutions based on glass,and ... has been,listed on the Frankfurt stock exchange since ...
... well known risk factor for prostate, breast and colon ... responsible for generating fat cells also plays an important ... Singapore have conducted, for the first time, a genome-wide ... gamma (PPARg), turns on various genes related to obesity. ...
... - Total revenue grew 35% to $63.7 ... 11 consecutive annual cycles - ... earnings per share of $0.27 in line with guidance, TUCSON, Ariz., Nov. ... for the third,quarter ended September 30, 2007. For the third quarter of ...
... recognition of,Alzheimer,s Awareness Month, The HealthCentral Network,s,( ... to encourage early detection and a better ... who suffer from the condition or,are caring ... The special Alzheimer,s Awareness online feature,( ...
Cached Medicine News:Health News:Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85 2Health News:Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85 3Health News:Medicare Sets Physician Payment Rate for Percutaneous Kidney Cryoablation 2Health News:Medicare Sets Physician Payment Rate for Percutaneous Kidney Cryoablation 3Health News:Researchers chart the genetic mechanisms behind the genesis of fat cells 2Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 2Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 3Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 4Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 5Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 6Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 7Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 8Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 9Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 10Health News:The HealthCentral Network Honors Alzheimer's Awareness Month 2
Semkin forceps with stops. Insulated....
Scoville-Greenwood bayonet forceps...
Angled 60 degree blades 5.5 mm....
... Accurately tests for Nystagmus when rotated ... high by 8" diameter. Light weight ... bearings for effortless spin mechanism. For ... patient. Includes both Adult and Pediatric ...
Medicine Products: